Walgreens Boots Alliance, Inc.

WBA

US9314271084

Drug Retailers

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
16.22 ^USD	+5.43%		+1.19%	-37.88%

12:17pm	Evercore ISI Adjusts Price Target on Walgreens Boots Alliance to $17 From $18, Keeps In Line Rating	MT
May. 31	Morgan Stanley Lowers Price Target on Walgreens Boots Alliance to $13 From $16, Maintains Underweight Rating	MT

Walgreens unit VillageMD to merge with Summit Health in $9 billion deal

November 07, 2022 at 09:22 am EST

Nov 7 (Reuters) - Walgreens Boots Alliance Inc's primary-care unit VillageMD said on Monday it will merge with urgent-care company Summit Health in a deal valued at nearly $9 billion including debt. (Reporting by Leroy Leo in Bengaluru; Editing by Devika Syamnath)

Latest news about Walgreens Boots Alliance, Inc.

Evercore ISI Adjusts Price Target on Walgreens Boots Alliance to $17 From $18, Keeps In Line Rating	06:17am	MT
Morgan Stanley Lowers Price Target on Walgreens Boots Alliance to $13 From $16, Maintains Underweight Rating	May. 31	MT
Price cuts, weaker spending may boost Fed's faith in inflation outlook	May. 31	RE
Nvidia soon to join the Dow Jones?	May. 29
Health Care Limits Losses Amid Defensive Bias - Health Care Roundup	May. 23	DJ
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	May. 23
The market is good to go until Nvidia’s next quarterly results	May. 23
Walgreens Boots Alliance Sells $400 Million of Cencora Shares	May. 23	MT
Walgreens further cuts stake in drug distributor Cencora	May. 22	RE
Walgreens reduces stake in Cencora	May. 22	RE
News Highlights : Top Company News of the Day - Tuesday at 1 PM ET	May. 21	DJ
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET	May. 21	DJ
Advanced Oxygen Therapy plans London float - Sky News	May. 16	AN
Walgreens to Sell Over-the-Counter Naloxone Anti-Narcotic Spray to Reverse Opioid Overdoses	May. 15	MT
Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray	May. 15	CI
Raspberry Pi helps lift gloom over London IPO market	May. 15	AN
Global markets live: Apple, Sony, Vodafone, Booking, Walmart...	May. 14
TD Cowen Adjusts Price Target on Walgreens Boots Alliance to $35 From $37	May. 14	MT
FTSE 100 remains flat amid UK labor data and corporate updates	May. 14
UK wage growth above forecasts; Greggs sales rise	May. 14	AN
Stocks to drift lower before US PPI print	May. 14	AN
Equities Close Mixed as Markets Weigh Consumer Inflation Survey	May. 13	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	May. 13	MT
Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey	May. 13	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	May. 13	MT

Chart Walgreens Boots Alliance, Inc.

Duration

Period

More charts

Company Profile

Walgreens Boots Alliance, Inc. specializes in the distribution of pharmaceutical products. Net sales break down by activity as follows: - retail distribution (87.2%): selling prescription drugs, OTC medicines, beauty and cosmetic products, etc. in the United States (90.9% of net sales) and internationally (9.1%). At the end of August 2023, the activity is carried out through 13,532 outlets (of which 8,706 located in the United States, Puerto Rico and the US Virgin Islands), and through the Internet; - wholesale distribution (8.1%). The remaining sales (4.7%) are from the healthcare Net sales break down geographically as follows: the United States (84%), Germany (8.1%), the United Kingdom (6.5%) and other (1.4%).

Sector

Drug Retailers

Calendar

2024-06-26 - Q3 2024 Earnings Release (Projected)

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Walgreens CEO on Narrowed Forecast, Shoppers Cutting Back Spending

March 28, 2024 at 03:59 pm EDT

Walgreens Boots Alliance, Inc. first light at the end of the tunnel?

November 27, 2023 at 10:22 am EST

More Strategies

Ratings for Walgreens Boots Alliance, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

16.22 USD

Average target price

22.58 USD

Spread / Average Target

+39.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
WALGREENS BOOTS ALLIANCE, INC.	-37.88%	13.99B
JD HEALTH INTERNATIONAL INC.	-32.35%	10.67B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-20.52%	6.75B
YIFENG PHARMACY CHAIN CO., LTD.	+12.54%	6.29B
MATSUKIYOCOCOKARA & CO.	-11.51%	5.88B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+75.00%	4.96B
NAHDI MEDICAL COMPANY	-2.48%	4.61B
CLICKS GROUP LIMITED	-9.20%	3.74B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-19.40%	3.16B
WELCIA HOLDINGS CO., LTD.	-12.17%	2.85B

Other Drug Retailers

Walgreens Boots Alliance, Inc.

Equities

WBA

US9314271084

Drug Retailers

Walgreens unit VillageMD to merge with Summit Health in $9 billion deal

EPS Revisions